Assessment of salivary gland function after (177)Lu-PSMA radioligand therapy: Current concepts in imaging and management Review

   


Authors: Mahajan, S.; Grewal, R. K.; Friedman, K. P.; Schöder, H.; Pandit-Taskar, N.
Review Title: Assessment of salivary gland function after (177)Lu-PSMA radioligand therapy: Current concepts in imaging and management
Abstract: Prostate specific membrane antigen (PSMA) is a transmembrane protein that is highly expressed on prostate epithelial cells and is strongly upregulated in prostate cancer. Radioligand therapy using beta-emitting Lutetium-177 (177Lu)-labeled-PSMA-617, a radiolabeled small molecule, has gained attention as a novel targeted therapy for metastatic prostate cancer, given its high affinity and long tumor retention, and rapid blood pool clearance. In March 2022, the United States Food and Drug administration has granted approval to the targeted 177Lu-PSMA-617 therapy for treatment of patients with PSMA-positive metastatic castration resistant prostate cancer, who have been previously treated with an androgen-receptor pathway inhibitor and taxane-based chemotherapy. Studies have demonstrated the adverse effects of this treatment, mainly encountered due to radiation exposure to non-target tissues. Salivary glands show high PSMA-ligand uptake and receive increased radiation dose secondary to accumulation of 177Lu-PSMA-617. This predisposes the glands to radiation-mediated toxicity. The exact mechanism, scope and severity of radiation-mediated salivary gland toxicity are not well understood, however, the strategies for its prevention and treatment are under evaluation. This review will focus on the current knowledge about salivary gland impairment post 177Lu labeled PSMA-based radioligand therapies, diagnostic methodologies, and imaging with emphasis on salivary gland scintigraphy. The preventive strategies and known treatment options would also be briefly highlighted. © 2022
Keywords: xerostomia; radioligand therapy; 177lu-psma-617; salivary gland dysfunction
Journal Title: Translational Oncology
Volume: 21
ISSN: 1936-5233
Publisher: Elsevier Science, Inc.  
Date Published: 2022-07-01
Start Page: 101445
Language: English
DOI: 10.1016/j.tranon.2022.101445
PROVIDER: scopus
PMCID: PMC9079342
PUBMED: 35523007
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129597111&doi=10.1016%2fj.tranon.2022.101445&partnerID=40&md5=eb32a926c1cef938d5a2545730c7d193
Notes: Part of special issue "Prostate-specific membrane antigen (PSMA) Therapeutics" -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Ravinder K Grewal
    82 Grewal
  2. Heiko Schoder
    551 Schoder
  3. Neeta Pandit-Taskar
    344 Pandit-Taskar
Related MSK Work